VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized subsidiaries, VCC MEDICAL and FBM-Pharma, which focus on special methods of personalized medicine.
Products, services, technology
VCC-001 is an autologous tumour lysate vaccine based on the individual patient’s tumour cells. Used in Renal
Cell Cancer (post-nephrectomy), VCC-001 shows:
- A highly specific immune response with evidence of excellent efficacy,
- A very favourable safety and side effects profile.
- https://vaccentis.com/
- +41 79 428 22 97
- Send an email
- Martin Munte
Some insights
VCC-001 demonstrated already a significant survival advantage in Phase III clinical trials: Patients with pT3 stage adjuvant RCC revealed 5- and 10-year OS rates of 71.3% and 53.6% in the study group and 65.4% and 36.2% in the control group (p = 0.022).
VCC-001 is an autologous tumour lysate vaccine based on the individual patient’s tumour cells. VCC-001 shows a highly specific immune response with evidence of excellent efficacy and a very favourable safety and side effects profile. This is the strongest form of personalized medicine.
All companies that bring significant benefits for patients to the market and are fully determined to fight diseases in all sectors of the Biotech industry.
We are fully committed to bring innovation from clinical development to the patient. Our capabilities are ranging from discovery to preclinical, and clinical stages, as well as to market access, and launch life cycles. We foster an open transparent culture and value entrepreneurship.
We make medical products that benefit patients!
Have the opportunity to engage with investors to be able to fulfil our business goals to bring VCC-001 to the market.
With venture capital firms, family offices, and high‑net‑worth investors.
